Thrilled to share our work characterising acquired resistance to immune checkpoint blockade (ICB) in the post-progression setting, now published in @jitcancer@sitcancer !
https://t.co/E7wwY9VhhN
Thrilled to share our work characterising acquired resistance to immune checkpoint blockade (ICB) in the post-progression setting, now published in @jitcancer@sitcancer !
https://t.co/E7wwY9VhhN
This work is an exemplar of a cross-functional and cross-institutional team effort, gathering diverse backgrounds and expertise to tackle a very important translational question. Huge thanks to all co-authors for all their contributions in shaping this work.
Only few places left!
🧐 Next Cam Comp Onco meeting
⏲️ March 15th, 3-6 pm
🛖 hosted by AZ at the DISC
📢 @OMRueda@AppleTreeWoman@RedaKeddar
❗️❗️Register by march 10th❗️❗️
https://t.co/DGhvqpG8Y0
Only few places left!
🧐 Next Cam Comp Onco meeting
⏲️ March 15th, 3-6 pm
🛖 hosted by AZ at the DISC
📢 @OMRueda@AppleTreeWoman@RedaKeddar
❗️❗️Register by march 10th❗️❗️
https://t.co/DGhvqpG8Y0
Miriam Merad, MD, PhD, Elected to the National Academy of Medicine for Seminal Work in Immunology and Cell Biology | Mount Sinai - New York https://t.co/jMZoL8Tga0
@IcahnMountSinai@SinaiImmunol@theNAMedicine
Thrilled to begin my tenure as the new president of @iuis_online! We are working toward demystifying immunology research, fostering global collaborations & bringing new immunotherapies to patients everywhere 🤝
Read more here: https://t.co/jlkzxuyApC